Gregory Vladimer News Today

Uses multi-omics to identify a biomarker which could be predictive of '546 response in the clinic Differentiated '546 development and patient enrichment strategy driven by Exscientia's precision

Combines precision oncology platform with single-cell sequencing and transcriptomics with aim to select patients most likely to benefit from GTAEXS-617 therapy Confirmed and identified CDK7-specific

Findings support deep learning ex vivo drug screening with patient tissue as a promising tool to identify effective, individual treatments in advanced blood cancer over conventional methods Custom

Study shows benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancers 54% of patients